DOCSLIB.ORG

Chemokines in Arthritis: Key Molecules in Pathogenesis and Potential Therapeutic Targets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chemokines in Arthritis: Key Molecules in Pathogenesis and Potential Therapeutic Targets For reprint orders, please contact: REVIEW [email protected] Chemokines in arthritis: key molecules in pathogenesis and potential therapeutic targets Frances Humby, An increasing wealth of evidence suggests an important role for chemokines and their Antonio Manzo & receptors in the pathogenesis of inflammation. In this review, the authors explore the role of Costantino Pitzalis† chemokines in inflammatory joint diseases, with particular emphasis on rheumatoid arthritis. †Author for correspondence Recent progress aimed at modulating the chemokine and chemokine receptor system for King’s College London School therapy will also be discussed. of Medicine, Guy’s, King’s College and St Thomas Hospitals, 5th Floor, Thomas Guy House, Guy’s Hospital, Rheumatoid arthritis (RA) is the most common share a tertiary structure, stabilized by four London, SE1 9RT, UK inflammatory joint disease [1], with an unknown cysteine residues that form disulfide bonds, dis- Tel.: +44 207 188 5903; etiology that results in the persistent inflamma- tinguishing them from the classical chemo- Fax: +44 207 188 5883; [email protected] tion of synovial tissue (ST) in the joints of attractant molecules (e.g., complement fragment affected patients. The synovitis that ensues peptides C3a and C5a and lipid molecules such results in cartilage and bone destruction and is as leukotriene B4 and platelet activating factor). linked with considerable morbidity [2]. Thus They have been subdivided into four families overall, RA is known to be associated with (Table 1) on the basis of the arrangement of their increased mortality [2,3]. Considerable work sug- cysteine residues. The two major subfamilies gests that an autoimmune process drives the have the cysteine residues adjacent to each other synovitis, which is characterized pathologically (cysteine-cysteine [CC] CK) or separated by one by proliferation and thickening of the lining amino acid (cysteine-x-cysteine [CXC] CK) [4]. layer, the phenomena of neoangiogenesis and a The other two families consist of first the CX3C mononuclear cell infiltrate. This includes CK, fractalkine/CX3CL1 [13], with three amino monocyte macrophages, B and T lymphocytes, acids separating the cysteine residues, and sec- dendritic cells, plasma cells (in some instances ond the cysteine (C) CK group, lympho- organized in typical lymphoid-like structures) tactin/XCL1 and SCM-1β/XCL2, with two and mast cells. The processes that result in these instead of four conserved cysteines [14] (see pathological appearances are the consequence of Table 1 for abbreviation definitions). an orchestrated action of a multitude of soluble All CKs act via seven transmembrane domain chemoattractants, in particular chemokines CK-Rs that are coupled to guanosine–tri- (CKs) and cell adhesion molecules that enable phosphate-binding proteins. The binding of a hematopoietic blood-borne cells to localize and CK to its cognate receptor can induce a wide be retained within the joint. CKs are chemo- spectrum of effects, including the arrest and tactic cytokines that play a crucial role in angio- firm adhesion of blood-borne cells on endo- genesis and leukocyte recruitment and exert thelial surfaces and transendothelial migration chemotactic activity towards a variety of cell into tissues. These events involve CKs on the types. Therefore, CKs and CK receptors surface of endothelial cells interacting with their (CK-Rs) have recently become the focus of con- cognate receptors on leukocytes triggering certed efforts to understand their mechanistic intracellular signals. This leads to integrin clus- role in the pathogenesis of inflammatory arthri- tering (increasing integrin avidity) and tis. Understanding their role and the pathways enhanced integrin affinity (through confor- involved may allow the possibility of targeting mational changes) [15], which is followed by them for therapy in RA. firm adhesion to the endothelium and leuko- Keywords: cell migration, cyte extravasation [16]. Once localized in the tis- chemokines, inflammation, Chemokines & chemokine receptors sues, the final positioning of various leukocyte lymphoid neogenesis, rheumatoid arthritis CKs are low molecular weight (8–14 Kd), struc- subsets is also driven by further gradients of turally-related, secreted or membrane-bound CKs. Therefore, CKs allow leukocytes to circu- proteins [4] that function as cell attractants. late from the bloodstream to specific organs and More than 50 human CKs have been character- move inside these tissues in a programmed fash- ized so far, along with 18 receptors [5–12]. They ion through spatial and temporal successions of 10.2217/17450816.1.1.53 © 2006 Future Medicine Ltd ISSN 1745-0816 Future Rheumatol. (2006) 1(1), 53–65 53 REVIEW – Humby, Manzo & Pitzalis CK gradients [17,18]. However, the activity of release of proteases from neutrophils and mono- CKs is not restricted simply to cell mobiliza- cytes, which potentiate inflammation [20]. CKs tion, as they can participate in cell activation, are also intimately involved in angiogenesis [21]. inducing the release of the content of Genetic analyses have shown that many CKs cytoplasmic storage granules, or by upregulating may have arisen from the reduplication of the expression of soluble- and membrane- ancestral genes [4] and many are clustered in bound molecules. Examples of the latter being certain chromosomal locations. Two main clus- the induction of the expression of ters have been recognized: CXC CKs clustering lymphotoxin (LT)β on B cells via BCA-1 at chromosome 4q12–13 and many CC CKs (BLC)/CXCL13 [19], and of the former, the located in another cluster at 17q11.2 [4]. Table 1. Human CXC, C, CC and CX3C chemokines and cognate receptors Common name ligand Systematic name Chemokine receptors C family Lymphotactin/SCM-1α/ATAC XCL1 XCR1 SCM-1β XCL2 XCR1 CC family I-309 CCL1 CCR8 MCP-1/MCAF/TDCF CCL2 CCR2 MIP-1 α/LD78α CCL3 CCR1,CCR5 LD78β CCL3L1 CCR1,CCR5 MIP-1β CCL4 CCR5 LAG-1 gene duplication CCL4L1 RANTES CCL5 CCR1, CCR3, CCR5 (C-10/MRP-2) CCL6 CCR1, CCR2, CCR3 MCP-3 CCL7 CCR1, CCR2, CCR3 MCP-2 CCL8 CCR2, CCR3,CCR5 (MIP-1γMRP-2) CCL9/CCL10 CCR1 Eotaxin CCL11 CCR3 (MCP-5) CCL12 CCR2 MCP-4 CCL13 CCR1, CCR2, CCR3 HCC-1 CCL14 CCR1,CCR5 HCC-2/lkn-1/MIP-1δ CCL15 CCR1,CCR3 HCC-4/LEC/LCC-1 CCL16 CCR1,CCR2 TARC CCL17 CCR4 DC-CK1/PARC/AMAC-1 CCL18 Unknown MIP-3β/ELC/exodus-3 CCL19 CCR7 MIP3α/LARC/exodus-1 CCL20 CCR6 6Ckine/SLC/exodus-2 CCL21 CCR7 MDC/STC-1 CCL22 CCR4 MPIF-1/CKβ8/CKβ8–1 CCL23 CCR1 Eotaxin-2/MPIF-2 CCL24 CCR3 TECK CCL25 CCR9 Eotaxin-3 CCL26 CCR3 CTACK/ILC CCL27 CCR10 MEC CCL28 CCR3/CCR10 AMAC: Alternative macrophage activation-associated chemokine; ATAC: Activation-induced T-cell-derived and chemokine-related cytokine; BCA: B-cell attracting; BLC: B lymphocyte chemokine; BRAK: Breast and kidney-expressed chemokine; C: Cysteine; CC: Cysteine-cysteine; CXC: Cysteine-x-cysteine; CTACK: Cutaneous T-cell attracting chemokine; DC: Dendritic cell; ELC: Epstein–Barr virus-induced molecule 1 ligand chemokine; ENA: Epithelial cell-derived neutrophil-activating protein; GCP: Granulocyte chemotactic protein; GRO: Growth related; HCC: Hemofiltrate cysteine-cysteine; IL: Interleukin; ILC: IL-11Ra-locus chemokine; IP: Interferon-γ inducible protein; LAG: Lymphocyte activating gene; LARC: Liver and activation-regulated chemokine; LCC: Liver CC chemokine; LEC: Liver-expressed chemokine; MCAF: Monocyte chemotactic and activating factor; MCP: Monocyte chemoattractant protein; MDC: Macrophage-derived chemokine; MEC: Mammary-enriched chemokine; MGSA: Melanoma growth stimulatory activity; Mig: Monokine induced by IFN-γ; MIP: Macrophage inflammatory protein; MPIF: Macrophage procoagulant inducing factor; MRP: Multidrug resistance-associated protein; NAP: Neutrophil activating protein; PARC: Pulmonary and activation- regulated chemokine; PF: Platelet factor; RANTES: Regulated on activation, normal T-cell-expressed and secreted; SCM: S-carboxymethyl; SDF: Stromal-cell derived factor; SLC: Secondary lymphoid organ chemokine; STC: Stem hematopoietic cells; TAC: T-cell-α chemoattractant; TARC: Thymus and activation-regulated chemokine; TDCF: Tumor-derived chemotactic factor; TECK: Thymus-expressed chemokine. 54 Future Rheumatol. (2006) 1(1) Chemokines in arthritis – REVIEW Table 1. Human CXC, C, CC and CX3C chemokines and cognate receptors (cont.). Common name ligand Systematic name Chemokine receptors CX3C family Fractalkine CX3CL1 CX3CR1 CXC chemokine/receptor family GRO-α/MGSA-α CXCL1 CXCR2 > CXCR1 GRO-β/MGSA-β CXCL2 CXCR2 GRO-γ/MGSA-γ CXCL3 CXCR2 PF4 CXCL4 Unknown ENA-78 CXCL5 CXCR2 GCP-2 CXCL6 CXCR1, CXCR2 NAP-2 CXCL7 CXCR2 IL-8 CXCL8 CXCR1, CXCR2 Mig CXCL9 CXCR3 IP-10 CXCL10 CXCR3 I-TAC CXCL11 CXCR3 SDF-1 α/β CXCL12 CXCR4 BCA-1(BLC) CXCL13 CXCR5 BRAK/bolekine CXCL14 Unknown (Lungkine) CXCL15 Unknown Small inducible cytokine B6 CXCL16 CXCR6 AMAC: Alternative macrophage activation-associated chemokine; ATAC: Activation-induced T-cell-derived and chemokine-related cytokine; BCA: B-cell attracting; BLC: B lymphocyte chemokine; BRAK: Breast and kidney-expressed chemokine; C: Cysteine; CC: Cysteine-cysteine; CXC: Cysteine-x-cysteine; CTACK: Cutaneous T-cell attracting chemokine; DC: Dendritic cell; ELC: Epstein–Barr virus-induced molecule 1 ligand chemokine; ENA: Epithelial cell-derived neutrophil-activating protein; GCP: Granulocyte chemotactic protein; GRO: Growth related; HCC: Hemofiltrate cysteine-cysteine; IL: Interleukin; ILC: IL-11Ra-locus chemokine; IP: Interferon-γ inducible protein; LAG: Lymphocyte activating
Load more

Recommended publications
  • Induces Homing of Antigen-Specific and Non Chemokine-Adjuvanted
    Chemokine-Adjuvanted Plasmid DNA Induces Homing of Antigen-Specific and Non −Antigen-Specific B and T Cells to the Intestinal and Genital Mucosae This information is current as of September 25, 2021. Yoann Aldon, Sven Kratochvil, Robin J. Shattock and Paul F. McKay J Immunol published online 8 January 2020 http://www.jimmunol.org/content/early/2020/01/07/jimmun ol.1901184 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2020/01/07/jimmunol.190118 Material 4.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 25, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Author Choice Freely available online through The Journal of Immunology Author Choice option Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2020 The Authors All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published January 8, 2020, doi:10.4049/jimmunol.1901184 The Journal of Immunology Chemokine-Adjuvanted Plasmid DNA Induces Homing of Antigen-Specific and Non–Antigen-Specific B and T Cells to the Intestinal and Genital Mucosae Yoann Aldon, Sven Kratochvil, Robin J.
    [Show full text]
  • Human B Cells Expression in Terminally Differentiating Induces
    1,25-Dihydroxyvitamin D3 Induces CCR10 Expression in Terminally Differentiating Human B Cells This information is current as Aiko-Konno Shirakawa, Daisuke Nagakubo, Kunio of September 28, 2021. Hieshima, Takashi Nakayama, Zhe Jin and Osamu Yoshie J Immunol 2008; 180:2786-2795; ; doi: 10.4049/jimmunol.180.5.2786 http://www.jimmunol.org/content/180/5/2786 Downloaded from References This article cites 55 articles, 29 of which you can access for free at: http://www.jimmunol.org/content/180/5/2786.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology 1,25-Dihydroxyvitamin D3 Induces CCR10 Expression in Terminally Differentiating Human B Cells1 Aiko-Konno Shirakawa,2 Daisuke Nagakubo,2 Kunio Hieshima, Takashi Nakayama, Zhe Jin, and Osamu Yoshie3 In the B cell lineage, CCR10 is known to be selectively expressed by plasma cells, especially those secreting IgA.
    [Show full text]
  • Antimicrobial Activity As a Chemokine with Broad-Spectrum CCL28 Has
    CCL28 Has Dual Roles in Mucosal Immunity as a Chemokine with Broad-Spectrum Antimicrobial Activity This information is current as Kunio Hieshima, Haruo Ohtani, Michiko Shibano, Dai of September 26, 2021. Izawa, Takashi Nakayama, Yuri Kawasaki, Fumio Shiba, Mitsuru Shiota, Fuminori Katou, Takuya Saito and Osamu Yoshie J Immunol 2003; 170:1452-1461; ; doi: 10.4049/jimmunol.170.3.1452 Downloaded from http://www.jimmunol.org/content/170/3/1452 References This article cites 36 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/170/3/1452.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 26, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology CCL28 Has Dual Roles in Mucosal Immunity as a Chemokine with Broad-Spectrum Antimicrobial Activity1 Kunio Hieshima,* Haruo Ohtani,2‡ Michiko Shibano,* Dai Izawa,* Takashi Nakayama,* Yuri Kawasaki,* Fumio Shiba,* Mitsuru Shiota,† Fuminori Katou,§ Takuya Saito,¶ and Osamu Yoshie3* CCL28 is a CC chemokine signaling via CCR10 and CCR3 that is selectively expressed in certain mucosal tissues such as exocrine glands, trachea, and colon.
    [Show full text]
  • The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors—A Review of Literature
    International Journal of Molecular Sciences Review The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors—A Review of Literature Jan Korbecki 1 , Klaudyna Kojder 2, Patrycja Kapczuk 1, Patrycja Kupnicka 1 , Barbara Gawro ´nska-Szklarz 3 , Izabela Gutowska 4 , Dariusz Chlubek 1 and Irena Baranowska-Bosiacka 1,* 1 Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta´nców Wielkopolskich 72 Av., 70-111 Szczecin, Poland; [email protected] (J.K.); [email protected] (P.K.); [email protected] (P.K.); [email protected] (D.C.) 2 Department of Anaesthesiology and Intensive Care, Pomeranian Medical University in Szczecin, Unii Lubelskiej 1, 71-281 Szczecin, Poland; [email protected] 3 Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University in Szczecin, Powsta´nców Wielkopolskich 72 Av., 70-111 Szczecin, Poland; [email protected] 4 Department of Medical Chemistry, Pomeranian Medical University in Szczecin, Powsta´nców Wlkp. 72 Av., 70-111 Szczecin, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-914661515 Abstract: Hypoxia is an integral component of the tumor microenvironment. Either as chronic or cycling hypoxia, it exerts a similar effect on cancer processes by activating hypoxia-inducible factor-1 (HIF-1) and nuclear factor (NF-κB), with cycling hypoxia showing a stronger proinflammatory influ- ence. One of the systems affected by hypoxia is the CXC chemokine system. This paper reviews all available information on hypoxia-induced changes in the expression of all CXC chemokines (CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8 (IL-8), CXCL9, CXCL10, CXCL11, CXCL12 Citation: Korbecki, J.; Kojder, K.; Kapczuk, P.; Kupnicka, P.; (SDF-1), CXCL13, CXCL14, CXCL15, CXCL16, CXCL17) as well as CXC chemokine receptors— Gawro´nska-Szklarz,B.; Gutowska, I.; CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CXCR7 and CXCR8.
    [Show full text]
  • The Chemokine System in Innate Immunity
    Downloaded from http://cshperspectives.cshlp.org/ on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press The Chemokine System in Innate Immunity Caroline L. Sokol and Andrew D. Luster Center for Immunology & Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114 Correspondence: [email protected] Chemokines are chemotactic cytokines that control the migration and positioning of immune cells in tissues and are critical for the function of the innate immune system. Chemokines control the release of innate immune cells from the bone marrow during homeostasis as well as in response to infection and inflammation. Theyalso recruit innate immune effectors out of the circulation and into the tissue where, in collaboration with other chemoattractants, they guide these cells to the very sites of tissue injury. Chemokine function is also critical for the positioning of innate immune sentinels in peripheral tissue and then, following innate immune activation, guiding these activated cells to the draining lymph node to initiate and imprint an adaptive immune response. In this review, we will highlight recent advances in understanding how chemokine function regulates the movement and positioning of innate immune cells at homeostasis and in response to acute inflammation, and then we will review how chemokine-mediated innate immune cell trafficking plays an essential role in linking the innate and adaptive immune responses. hemokines are chemotactic cytokines that with emphasis placed on its role in the innate Ccontrol cell migration and cell positioning immune system. throughout development, homeostasis, and in- flammation. The immune system, which is de- pendent on the coordinated migration of cells, CHEMOKINES AND CHEMOKINE RECEPTORS is particularly dependent on chemokines for its function.
    [Show full text]
  • Immune Evasion by Murine Melanoma Mediated Through CC Chemokine
    Immune Evasion by Murine Melanoma Mediated through CC Chemokine Receptor-10 Takashi Murakami,1 Adela R. Cardones,1 Steven E. Finkelstein,2 Nicholas P. Restifo,2 Brenda A. Klaunberg,5 Frank O. Nestle,4 S. Sianna Castillo,3 Phillip A. Dennis,3 and Sam T. Hwang1 1Dermatology, 2Surgery, and 3Cancer Therapeutics Branches, CCR, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892 4National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892 5Department of Dermatology, University of Zürich Hospital, CH-8091 Zürich, Switzerland Abstract Human melanoma cells frequently express CC chemokine receptor (CCR)10, a receptor whose ligand (CCL27) is constitutively produced by keratinocytes. Compared with B16 murine melanoma, cells rendered more immunogenic via overexpression of luciferase, B16 cells that overexpressed both luciferase and CCR10 resisted host immune responses and readily formed tumors. In vitro, exposure of tumor cells to CCL27 led to rapid activation of Akt, resistance to cell death induced by melanoma antigen-specific cytotoxic T cells, and phosphatidylinositol-3- kinase (PI3K)–dependent protection from apoptosis induced by Fas cross-linking. In vivo, cutaneous injection of neutralizing antibodies to endogenous CCL27 blocked growth of CCR10-expressing melanoma cells. We propose that CCR10 engagement by locally produced CCL27 allows melanoma cells to escape host immune antitumor killing mechanisms (possibly through activation of PI3K/Akt), thereby providing a means for tumor progression. Key words: metastasis • chemokine receptor • cancer • cell signaling Introduction Malignant melanoma is a potentially fatal skin cancer that is In this paper, we explore the role of chemokine recep- increasing in incidence (1). The ability of tumor cells to tors in the context of tumor escape from immune cell avoid immune surveillance is likely to be central to the clearance mechanisms.
    [Show full text]
  • Chloride Channels Regulate Differentiation and Barrier Functions
    RESEARCH ARTICLE Chloride channels regulate differentiation and barrier functions of the mammalian airway Mu He1†*, Bing Wu2†, Wenlei Ye1, Daniel D Le2, Adriane W Sinclair3,4, Valeria Padovano5, Yuzhang Chen6, Ke-Xin Li1, Rene Sit2, Michelle Tan2, Michael J Caplan5, Norma Neff2, Yuh Nung Jan1,7,8, Spyros Darmanis2*, Lily Yeh Jan1,7,8* 1Department of Physiology, University of California, San Francisco, San Francisco, United States; 2Chan Zuckerberg Biohub, San Francisco, United States; 3Department of Urology, University of California, San Francisco, San Francisco, United States; 4Division of Pediatric Urology, University of California, San Francisco, Benioff Children’s Hospital, San Francisco, United States; 5Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Heaven, United States; 6Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, United States; 7Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States; 8Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, United States *For correspondence: Abstract The conducting airway forms a protective mucosal barrier and is the primary target of [email protected] (MH); [email protected] airway disorders. The molecular events required for the formation and function of the airway (SD); mucosal barrier, as well as the mechanisms by which barrier dysfunction leads to early onset airway [email protected] (LYJ) diseases,
    [Show full text]
  • CCL28 a Mucosal Chemokine That Has a Protective Role in the MALT
    UC Irvine UC Irvine Electronic Theses and Dissertations Title Functional Characterization of IL-40 a novel B cell cytokine and Physiological implications of CCL28 ablation Permalink https://escholarship.org/uc/item/2m7018vx Author Vazquez, Monica Ivonne Publication Date 2015 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA, IRVINE Functional Characterization of IL-40 a novel B cell cytokine and Physiological Implications of CCL28 ablation DISSERTATION Submitted in Partial Satisfaction of the Requirements for the Degree of DOCTOR OF PHILOSOPHY In Biomedical Sciences By Monica Ivonne Vazquez Dissertation Committee: Professor Albert Zlotnik, Chair Professor Kenneth J. Longmuir Professor Craig M. Walsh 2015 Portions of Chapter 1 © 2015 Elselvier Ltd. All other chapters © 2015 Monica Ivonne Vazquez DEDICATION TO My husband Brian Vazquez And son Isaiah Vazquez They have been part of my entire life as a student from my undergraduate years to my graduate career. They both provided a much needed sense of balance and always brought me back to what matters the most: Family. My little girl, Penelope, who always brings a smile to face and has given me the strength to continue. Getsemani, expected April 7, 2015, who I cannot wait to meet. Thank you for your unending love and support. ii TABLE OF CONTENTS Page LIST OF FIGURES iv-vi LIST OF TABLES vii ACKNOWLEDGMENTS viii CURRICULUM VITAE ix-x LIST OF ABBREVIATIONS xi-xiv ABSTRACT OF THE DISSERTATION xv-xvi Chapter
    [Show full text]
  • Metamorphic Protein Folding Encodes Multiple Anti-Candida Mechanisms in XCL1
    pathogens Article Metamorphic Protein Folding Encodes Multiple Anti-Candida Mechanisms in XCL1 Acacia F. Dishman 1,2,†, Jie He 3,†, Brian F. Volkman 1,* and Anna R. Huppler 3,* 1 Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA; [email protected] 2 Medical Scientist Training Program, Medical College of Wisconsin, Milwaukee, WI 53226, USA 3 Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA; [email protected] * Correspondence: [email protected] (B.F.V.); [email protected] (A.R.H.) † These authors contributed equally. Abstract: Candida species cause serious infections requiring prolonged and sometimes toxic therapy. Antimicrobial proteins, such as chemokines, hold great interest as potential additions to the small number of available antifungal drugs. Metamorphic proteins reversibly switch between multiple different folded structures. XCL1 is a metamorphic, antimicrobial chemokine that interconverts between the conserved chemokine fold (an α–β monomer) and an alternate fold (an all-β dimer). Previous work has shown that human XCL1 kills C. albicans but has not assessed whether one or both XCL1 folds perform this activity. Here, we use structurally locked engineered XCL1 variants and Candida killing assays, adenylate kinase release assays, and propidium iodide uptake assays to demonstrate that both XCL1 folds kill Candida, but they do so via different mechanisms. Our results suggest that the alternate fold kills via membrane disruption, consistent with previous work, and the chemokine fold does not. XCL1 fold-switching thus provides a mechanism to regulate Citation: Dishman, A.F.; He, J.; the XCL1 mode of antifungal killing, which could protect surrounding tissue from damage associ- Volkman, B.F.; Huppler, A.R.
    [Show full text]
  • Role of Chemokines in Hepatocellular Carcinoma (Review)
    ONCOLOGY REPORTS 45: 809-823, 2021 Role of chemokines in hepatocellular carcinoma (Review) DONGDONG XUE1*, YA ZHENG2*, JUNYE WEN1, JINGZHAO HAN1, HONGFANG TUO1, YIFAN LIU1 and YANHUI PENG1 1Department of Hepatobiliary Surgery, Hebei General Hospital, Shijiazhuang, Hebei 050051; 2Medical Center Laboratory, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai 200065, P.R. China Received September 5, 2020; Accepted December 4, 2020 DOI: 10.3892/or.2020.7906 Abstract. Hepatocellular carcinoma (HCC) is a prevalent 1. Introduction malignant tumor worldwide, with an unsatisfactory prognosis, although treatments are improving. One of the main challenges Hepatocellular carcinoma (HCC) is the sixth most common for the treatment of HCC is the prevention or management type of cancer worldwide and the third leading cause of of recurrence and metastasis of HCC. It has been found that cancer-associated death (1). Most patients cannot undergo chemokines and their receptors serve a pivotal role in HCC radical surgery due to the presence of intrahepatic or distant progression. In the present review, the literature on the multi- organ metastases, and at present, the primary treatment methods factorial roles of exosomes in HCC from PubMed, Cochrane for HCC include surgery, local ablation therapy and radiation library and Embase were obtained, with a specific focus on intervention (2). These methods allow for effective treatment the functions and mechanisms of chemokines in HCC. To and management of patients with HCC during the early stages, date, >50 chemokines have been found, which can be divided with 5-year survival rates as high as 70% (3). Despite the into four families: CXC, CX3C, CC and XC, according to the continuous development of traditional treatment methods, the different positions of the conserved N-terminal cysteine resi- issue of recurrence and metastasis of HCC, causing adverse dues.
    [Show full text]
  • Epithelial Inflammation Is Associated with CCL28 Production and the Recruitment of Regulatory T Cells Expressing CCR10
    Epithelial Inflammation Is Associated with CCL28 Production and the Recruitment of Regulatory T Cells Expressing CCR10 This information is current as Bertus Eksteen, Alice Miles, Stuart M. Curbishley, Chris of September 26, 2021. Tselepis, Allister J. Grant, Lucy S. K. Walker and David H. Adams J Immunol 2006; 177:593-603; ; doi: 10.4049/jimmunol.177.1.593 http://www.jimmunol.org/content/177/1/593 Downloaded from References This article cites 51 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/177/1/593.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Epithelial Inflammation Is Associated with CCL28 Production and the Recruitment of Regulatory T Cells Expressing CCR101 Bertus Eksteen,* Alice Miles,* Stuart M. Curbishley,* Chris Tselepis,‡ Allister J.
    [Show full text]
  • Ccl27/Ccl2 Ccl28
    UNIVERSITY OF CALIFORNIA, SAN DIEGO Structural and Functional Analysis of the Chemokine CCL27 and the Expression and Purification of Silent Chemokine Receptors D6 and DARC A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Chemistry and Biochemistry by Ariane L. Jansma Committee in charge: Professor Tracy M. Handel, Chair Professor Patricia Jennings, Co-Chair Professor William Gerwick Professor Susan Taylor Asst. Professor Faik A. Tezcan 2009 This Dissertation of Ariane L. Jansma is approved, and it is acceptable in quality and form for publication on microfilm and electronically: ________________________________________________________ ________________________________________________________ ________________________________________________________ ________________________________________________________ Co-Chair ________________________________________________________ Chair iv TABLE OF CONTENTS Signature Page ................................................................................................................ iii Table of Contents............................................................................................................. iv List of Figures.................................................................................................................... x List of Tables...................................................................................................................xiii List of Abbreviations........................................................................................................xiv
    [Show full text]